Holen Sie sich die Stockscreener-App
5.484
0.00%
0.004
Schlusskurs vom Vortag:
$5.48
Offen:
$5.47
24-Stunden-Volumen:
830.42K
Relative Volume:
0.40
Marktkapitalisierung:
$945.79M
Einnahmen:
$246.03M
Nettoeinkommen (Verlust:
$-32.00M
KGV:
-25.81
EPS:
-0.2125
Netto-Cashflow:
$-16.78M
1W Leistung:
-5.68%
1M Leistung:
-19.65%
6M Leistung:
-26.84%
1J Leistung:
+20.18%
1-Tages-Spanne:
$5.445
$5.615
1-Wochen-Bereich:
$5.382
$5.865
52-Wochen-Spanne:
$3.805
$10.08
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
Firmenname
Xeris Biopharma Holdings Inc
Sektor
Branche
Telefon
844-445-5704
Adresse
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Compare XERS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
5.485 | 944.92M | 246.03M | -32.00M | -16.78M | -0.2125 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.66 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.82 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
705.63 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.35 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
283.89 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-08-12 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-11-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-03-28 | Eingeleitet | Oppenheimer | Outperform |
| 2023-08-28 | Eingeleitet | Craig Hallum | Buy |
| 2022-10-21 | Eingeleitet | Jefferies | Buy |
| 2022-04-28 | Eingeleitet | Craig Hallum | Buy |
| 2021-11-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-10-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-02-18 | Eingeleitet | Piper Sandler | Overweight |
| 2018-07-16 | Eingeleitet | Jefferies | Buy |
| 2018-07-16 | Eingeleitet | Leerink Partners | Outperform |
| 2018-07-16 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Xeris Biopharma Holdings Inc Aktie (XERS) Neueste Nachrichten
Xeris Biopharma (XERS) Q4 2025 Earnings Transcript - AOL.com
Assessing Xeris Biopharma Holdings (XERS) Valuation After Profitability Milestone And 2026 Revenue Guidance - Sahm
Momentum Shift: Will Xeris Biopharma Holdings Inc benefit from seasonalityJuly 2025 Update & Stepwise Trade Signal Implementation - baoquankhu1.vn
Xeris Biopharma (NASDAQ:XERS) Upgraded by Wall Street Zen to Strong-Buy Rating - MarketBeat
Xeris Biopharma: Q4 Earnings Snapshot - JG-TC.com
Xeris Biopharma Holdings, Inc. Experiences Evaluation Revision Amid Market Dynamics and Performance Trends - Markets Mojo
Xeris Biopharma Hits Day Low of $5.80 Amid Price Pressure - Markets Mojo
Why Is CORT Stock Falling Today? - Stocktwits
HC Wainwright Forecasts Xeris Biopharma Q1 Earnings - MarketBeat
Beth Hecht Sells 16,667 Shares of Xeris Biopharma Holdings Inc (XERS) - GuruFocus
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Decoding Xeris Biopharma Holdings Inc (XERS): A Strategic SWOT I - GuruFocus
Xeris Biopharma (NASDAQ:XERS) Insider Sells $104,168.75 in Stock - MarketBeat
Biopharma Appears a Safe Bet Now, So I'm Adding Two Names - TheStreet Pro
Xeris Biopharma: Undervalued Given The Potential Of Its Drug Portfolio (NASDAQ:XERS) - Seeking Alpha
HC Wainwright Predicts Xeris Biopharma Q2 Earnings - MarketBeat
XERS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Xeris Biopharma Balances New Profitability With Recorlev Patent Battles - Yahoo Finance
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2025 Earnings Call Transcript - Insider Monkey
Earnings call transcript: Xeris Biopharma’s Q4 2025 earnings beat estimates, stock surges - Investing.com Australia
Xeris Biopharma Holdings, Inc.Common Stock (NQ: XERS - The Chronicle-Journal
Xeris Biopharma Q4 2025 Earnings Call Transcript - MarketBeat
Xeris Biopharma (XERS) Turns Trailing Profitability Into Test Of Bullish Growth Narrative - simplywall.st
Xeris Biopharma Holdings Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Xeris Biopharma (NASDAQ:XERS) Issues Earnings Results - MarketBeat
Beth Hecht 10b5-1 sales reported for XERS (NASDAQ: XERS) - Stock Titan
XERS: Achieved first annual net profit and 43.7% revenue growth, led by Recorlev's strong performance - TradingView
Xeris Biopharma (NASDAQ: XERS) outlines endocrine and neuro focus - Stock Titan
Xeris Biopharma Holdings Inc (XERS) Q4 2025 Earnings Call Highli - GuruFocus
Today's Analyst Update: XERS Rating Reiterated at Buy by HC Wain - GuruFocus
Xeris Biopharma (NASDAQ:XERS) Receives Buy Rating from HC Wainwright - MarketBeat
Xeris Biopharma Holdings, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Xeris Biopharma (NASDAQ:XERS) Shares Gap UpHere's What Happened - MarketBeat
Xeris Biopharma Q4 Earnings Call Highlights - MarketBeat
Xeris Biopharma Q4 product revenue USD 83.43 million versus Ibes estimate USD 82.3 million - marketscreener.com
Xeris Biopharma (XERS) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
Xeris Biopharma (XERS) Q4 Earnings and Revenues Surpass Estimates - Yahoo Finance
XERS Projects Strong Growth for FY26 with Significant Revenue In - GuruFocus
Xeris (XERS) Sees Strong Q4 Revenue Growth - GuruFocus
(XERS) Xeris Biopharma Expects 2026 Total Revenue Range $375M to $390M, vs. FactSet Est of $368M - marketscreener.com
Earnings Flash (XERS) Xeris Biopharma Holdings, Inc. Reports Q4 Revenue $85.8M, vs. FactSet Est of $82.2M - marketscreener.com
Xeris Bi - Bitget
Xeris Biopharma stock up nearly 3% after Q4 EPS beat, above estimate guidance By Investing.com - Investing.com South Africa
Xeris Biopharma stock up nearly 3% after Q4 EPS beat, above estimate guidance - Investing.com
Xeris Biopharma Reports Record Performance for Q4 and Full Year 2025 - TradingView
XERS: Record 2025 revenue and profitability set the stage for over 30% growth in 2026 - TradingView
Record 2025 results as Xeris Biopharma (XERS) guides for 30%+ 2026 growth - Stock Titan
Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance - Business Wire
A Look At Xeris Biopharma Holdings (XERS) Valuation As It Fights To Protect Recorlev Exclusivity - Yahoo Finance
Xeris Biopharma Holdings (XERS) Is Down 7.4% After Suing to Block Recorlev Generics Until 2040 - simplywall.st
Xeris Biopharma (NASDAQ:XERS) Trading Down 8.3%Should You Sell? - MarketBeat
Finanzdaten der Xeris Biopharma Holdings Inc-Aktie (XERS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Xeris Biopharma Holdings Inc-Aktie (XERS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hecht Beth | See Remarks |
Mar 02 '26 |
Sale |
6.25 |
16,667 |
104,086 |
1,226,507 |
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):